@article {JARDEL23, author = {PAULINE JARDEL and ST{\'E}PHANE VIGNOT and BRUNO CUTULI and ANNE CREISSON and SYLVIE VASS and EMMANUEL BARRANGER and JULIETTE THARIAT}, title = {Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review}, volume = {38}, number = {1}, pages = {23--31}, year = {2018}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Guidelines for radiotherapy in male breast cancer (MBC) are lacking. Some extrapolate the results from female breast cancer trials, while others advocate systematic adjuvant irradiation. We evaluated clinical practices and outcomes with respect to radiation therapy in MBC treated with locoregional irradiation in the adjuvant setting using a systematic literature review. Material and Methods: We included studies with data about adjuvant radiotherapy published between 1984 and 2017 and including at least 40 patients. Results: We found 29 retrospective series, 10,065 men were diagnosed with breast cancer; 3-100\% (mean=54\%) received adjuvant radiotherapy. Tumor size and nodal involvement were the strongest prognostic factors. Approximatively half of all cases had nodal metastases. Radiation therapy improved locoregional control in six series, overall survival in three and distant metastasis-free survival in one. Conclusion: MBC is diagnosed at a highly advanced stage and may be linked with poorer outcomes. Adjuvant radiation therapy must, at least, be proposed to men with positive nodes. Despite the large number of cases gathered here, arguments for radiotherapy in other prognostic subgroups (especially in pN0) may exist but are not well supported.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/1/23}, eprint = {https://ar.iiarjournals.org/content/38/1/23.full.pdf}, journal = {Anticancer Research} }